London, 30 January 2017 – MRC Technology, an independent life science medical research charity, has appointed Steve Visscher CBE, currently BBSRC Deputy Chief Executive – International, to its board of trustees.
MRC Technology (MRCT) progresses medical research in areas where there is unmet patient need. It has helped to launch treatments for advanced melanoma, non-small-cell lung cancer, rheumatoid arthritis, multiple sclerosis and Crohn’s disease. The charity’s trustees have extensive expertise across the biomedical sciences, biotech and pharma industry, finance, law and medicine to support strategic direction in the delivery of its charitable objects.
Dr John Stageman, Chairman, MRC Technology, said: “I am delighted to welcome Steve to the board of trustees. Our board plays a pivotal role in ensuring the charity stays focused on the activities that will make the biggest impact to improve patients’ lives. Collaborative working with academia, healthcare companies and charities is a key strength for us, and Steve’s extensive experience of Research Council leadership, strategic finance and building international research partnerships will be a great asset to the board at this exciting time in MRCT’s development.”
Steve Visscher commented: “MRC Technology has a unique and valuable role among medical charities. I look forward to contributing to its strategic development as it deploys proven research and commercial expertise in new and established ways to further its charitable goals.”